Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 8, Issue 11, pp. 1407-1425
PubMed
Published By
Print ISSN
Online ISSN
History
- Received April 9, 2020
- Revision received July 3, 2020
- Accepted September 8, 2020
- Published first September 15, 2020.
Article Versions
- Previous version (September 15, 2020 - 05:51).
- Previous version (October 7, 2020 - 05:38).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Mariana C. Silva1,2,#,
- Ângela Fernandes1,#,
- Maria Oliveira1,
- Carlos Resende1,
- Alexandra Correia1,2,
- Julio C. de-Freitas-Junior3,
- Aonghus Lavelle4,
- Jéssica Andrade-da-Costa3,
- Magdalena Leander5,6,
- Helena Xavier-Ferreira1,2,
- José Bessa1,
- Carina Pereira7,8,
- Rui M. Henrique9,10,
- Fátima Carneiro1,11,12,
- Mário Dinis-Ribeiro7,13,
- Ricardo Marcos-Pinto2,14,15,
- Margarida Lima5,6,
- Bernd Lepenies16,17,
- Harry Sokol4,18,19,
- José C. Machado1,12,
- Manuel Vilanova1,2, and
- Salomé S. Pinho1,12,*
- 1Institute for Research and Innovation in Health (i3S), University of Porto, Porto, Portugal.
- 2Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
- 3Cellular and Molecular Oncobiology Program, Brazilian National Cancer Institute (INCA), Rio de Janeiro, Brazil.
- 4Sorbonne Université, INSERM, Saint-Antoine Research Center (CRSA), Paris, France.
- 5Department of Hematology, Hospital Center of Porto, Porto, Portugal.
- 6Multidisciplinary Unit for Biomedical Research, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
- 7CINTESIS – Centre for Health Technology and Services Research, University of Porto, Porto, Portugal.
- 8Molecular Oncology and Viral Pathology Group, IPO Porto Research Group (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
- 9Department of Pathology and Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
- 10Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto, Portugal.
- 11Department of Pathology, Hospital Center of São João, Porto, Portugal.
- 12Faculty of Medicine, University of Porto, Porto, Portugal.
- 13Department of Gastroenterology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
- 14Department of Gastroenterology, Hospital Center of Porto, Porto, Portugal.
- 15Medical Faculty, Centre for Research in Health Technologies and Information Systems, Porto, Portugal.
- 16Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Potsdam, Germany.
- 17Immunology Unit and Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover, Germany.
- 18INRA, UMR1319 Micalis, AgroParisTech, Jouy-en-Josas, France.
- 19Department of Gastroenterology, Saint Antoine Hospital, Assistance Publique - Hopitaux de Paris, Sorbonne Universités, Paris, France.
- ↵*Corresponding Author:
Salomé S. Pinho, Institute for Research and Innovation in Health (i3S), University of Porto, Alfredo Allen Street 208, Porto 4200-135, Portugal. Phone: 3512-2040-8800, ext. 7110; Fax: 3512-2557-0799; E-mail: salomep{at}ipatimup.pt
↵#M.C. Silva and Â. Fernandes contributed equally to this article.
November 2020
Volume 8, Issue 11
Volume 8, Issue 11
Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression
Jump to section
Advertisement